Myeloablative Allo Sct In Failed Auto Pbsct

Freytes et al.15 recently published a retrospective analysis of IBMTR data collected from 1990 to 1999 on 114 lymphoma (N = 35 Hodgkin's disease and N = 79 NHL) patients who received a myeloablative allo SCT after a failed auto SCT. Sixteen patients had low-grade

Table 65.3 Reasons for clinicians and investigators to consider allo SCT rather than auto SCT

■ Resistance to initial therapy

■ Resistance to salvage therapy

■ Resistance to both initial and salvage therapy

■ Bone marrow histologic (gross) involvement

■ Failure to harvest auto PBSC

■ Relapse after auto SCT

Was this article helpful?

0 0

Post a comment